2-ethyl-5-nitrothiophene | 65967-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-ethyl-5-nitrothiophene
• 英文别名: 5-nitro-2-ethylthiophene
• CAS: 65967-46-6
• 化学式: C₆H₇NO₂S
• 分子量: 157.193
• InChiKey: HDPSKNGMKVEYGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 2-ethyl-5-nitrothiophene 在 镍 氢气 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-acetylamino-2-ethylthiophene
  参考文献：
  名称：

  5-硝基-2R-噻吩的还原酰化

  摘要：

  DOI：

  10.1007/bf00546728
• 作为产物：
  描述：

  2-乙基噻吩 在 硝酸 、 乙酸酐 作用下， 生成 2-ethyl-5-nitrothiophene
  参考文献：
  名称：

  Investigation of the kinetics of the nitration of thiophene derivatives

  摘要：

  DOI：

  10.1007/bf00512952

文献信息

• Synthesis of Dinitro-Substituted Furans, Thiophenes, and Azoles
  作者：Alan Katritzky、Anatoliy Vakulenko、Jothilingam Sivapackiam、Bogdan Draghici、Reddy Damavarapu

  DOI：10.1055/s-2008-1032187

  日期：2008.3

  nitration of the corresponding mononitro furans with fuming nitric acid, thiophenes with acetyl nitrate, and thiazoles with trifluoroacetyl nitrate, gave dinitro-substituted furans, thiophenes, and thiazoles. The nitrations of 2-alkylthiophenes with 3 and 5 molar equivalents of acetyl nitrate, generated in situ, are discussed. Reactions of the mononitro furans with fuming nitric acid gave 1,1,5,5-tetrasubstituted

  相应的单硝基呋喃用发烟硝酸直接硝化，噻吩用乙酰硝酸酯直接硝化，噻唑用三氟乙酰硝酸酯直接硝化，得到二硝基取代的呋喃、噻吩和噻唑。讨论了原位生成的 2-烷基噻吩与 3 和 5 摩尔当量的乙酰硝酸酯的硝化反应。单硝基呋喃与发烟硝酸反应生成 1,1,5,5-四取代二氢呋喃作为副产物。用肼或其甲基或苯基衍生物处理 5-甲基-4-硝基异恶唑，然后用过氧化氢 (50%) 氧化相应的 4-氨基-5-硝基-1H-吡唑，得到 4,5-二硝基 -1H -吡唑。1-烷基-3,5-二硝基-1H-[1,2,4]三唑的安全一锅法合成是由双氰胺开发的。
• BRIDGED CARBAMATE MACROLIDES
  申请人：Kim Heejin

  公开号：US20080027012A1

  公开（公告）日：2008-01-31

  The present invention discloses compounds of formulae (I) and (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了式(I)和(II)的化合物或其药学上可接受的盐、酯或前药：这些化合物具有抗菌性能。本发明还涉及含有上述化合物的药物组合物，用于治疗需要抗生素治疗的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• [EN] USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD)<br/>[FR] UTILISATION DE COMPOSITIONS MODULANT LA STRUCTURE DE LA CHROMATINE CONTRE LA MALADIE DU GREFFON CONTRE L'HÔTE (GVHD)
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016073903A1

  公开（公告）日：2016-05-12

  In some aspects, the instant disclosure relates to methods of treating chronic graft versus host disease (cGVHD). In some embodiments, the method comprises administering to a subject in need thereof a EZH2 inhibitor, a Bcl6 inhibitor and/or BRD4 inhibitor. The present disclosure is based, at least in part, on the discovery that enhancer of zeste homolog 2 (EZH2) inhibitors, B-cell lymphoma 6 protein (Bcl6) inhibitors and/or bromodomain-containing protein 4 (BRD4) inhibitors can be used to treat chronic graft versus host disease (cGVHD).

  在某些方面，瞬时披露涉及治疗慢性移植物抗宿主病（cGVHD）的方法。在某些实施例中，该方法包括向需要该方法的受试者施用EZH2抑制剂、Bcl6抑制剂和/或BRD4抑制剂。本公开至少部分地基于发现，增强子of zeste同源物2（EZH2）抑制剂、B细胞淋巴瘤6蛋白（Bcl6）抑制剂和/或含有bromodomain的蛋白4（BRD4）抑制剂可用于治疗慢性移植物抗宿主病（cGVHD）。
• 3,6-Bridged 9,12-oxolides
  申请人：Or Sun Yat

  公开号：US20070232554A1

  公开（公告）日：2007-10-04

  The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明揭示了公式（I）的化合物或其药学上可接受的盐、酯或前药：具有抗菌性能。本发明还涉及包含上述化合物的制药组合物，用于治疗需要抗生素治疗的受体。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受体的细菌感染的方法。本发明还包括制备本发明化合物的方法。
• Oxazolidinone Compounds and Compositions and Methods Related Thereto
  申请人：Cano Montserrat

  公开号：US20090005369A1

  公开（公告）日：2009-01-01

  The invention provides new oxazolidinones of formula (I), where R1, R2, R3 and R4 are independently selected from H, F and Cl; A is certain heterocycles optionally substituted; X is selected from O, S, NR8 and CR8R9; R8 and R9 having different meanings; Y is selected from O, S, SO, SO2, NO, NR11 and CR11R12; R11 and R12 having different meanings; and n is selected from 0 and 1. It also provides different processes for the preparation of such compounds. Oxazolidinones compounds of formula (I) are active against Gram-positive and some Gram-negative human and veterinary pathogens with a weak monoamine oxidase (MAO) inhibitory activity. They are useful for the treatment of bacterial infections.

  本发明提供了式(I)的新型噁唑烷酮，其中R1、R2、R3和R4独立地选自H、F和Cl；A是某些杂环，可选地被取代；X选自O、S、NR8和CR8R9；R8和R9具有不同的含义；Y选自O、S、SO、SO2、NO、NR11和CR11R12；R11和R12具有不同的含义；n选自0和1。本发明还提供了制备这种化合物的不同方法。式(I)的噁唑烷酮化合物对革兰氏阳性和一些革兰氏阴性的人类和兽医病原体具有弱的单胺氧化酶（MAO）抑制活性。它们对治疗细菌感染有用。